# Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma

> **NCT00918333** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 124 (actual)

## Conditions studied

- Adult Nasal Type Extranodal NK/T-cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angioimmunoblastic T-cell Lymphoma
- B-cell Adult Acute Lymphoblastic Leukemia
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
- Hepatosplenic T-cell Lymphoma
- Nodal Marginal Zone B-cell Lymphoma
- Post-transplant Lymphoproliferative Disorder
- Primary Central Nervous System Non-Hodgkin Lymphoma
- Recurrent Adult Acute Lymphoblastic Leukemia
- Recurrent Adult Burkitt Lymphoma
- Recurrent Adult Diffuse Large Cell Lymphoma
- Recurrent Adult Hodgkin Lymphoma
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Adult T-cell Leukemia/Lymphoma
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Multiple Myeloma
- Splenic Marginal Zone Lymphoma
- T-cell Adult Acute Lymphoblastic Leukemia
- Waldenström Macroglobulinemia

## Interventions

- **DRUG:** panobinostat
- **DRUG:** everolimus
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00918333
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2015-12-01
- **Final completion:** 2019-07-16
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2020-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00918333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00918333, "Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00918333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*